858855-18-2

Basic information

• Product Name: 4-bromo-2-chloro-6-iodophenol
• Synonyms: 4-bromo-2-chloro-6-iodophenol
• CAS NO: 858855-18-2
• Molecular Weight: 333.351
• Mol File: 858855-18-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-bromo-2-chloro-6-iodophenol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-2-chloro-6-iodophenol(858855-18-2)
• EPA Substance Registry System: 4-bromo-2-chloro-6-iodophenol(858855-18-2)

Safety Data

• Hazardous Substances Data: 858855-18-2(Hazardous Substances Data)

Upstream product

• 50638-47-6 4-bromo-2-chloro-1-methoxybenzene 
• 4526-56-1 2,4-dibromo-6-chlorophenol 
• 3964-56-5 4-bromo-2-chlorophenol 

Relevant articles and documents

MULTICYCLIC COMPOUNDS AND USES THEREOF

The present invention relates to multicyclic compounds containing a urea or a guanidine moiety, or pharmaceutically acceptable salts or compositions thereof represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof and pharmaceutical comopositions comprising the multicyclic compounds. The invention also relates to a method for treating a disease or disorder selected from cancer (e.g., lymphoma, such as mantle cell lymphoma), a neurodegenerative disease, an inflammatory diseases or an immune system disease (e.g., a T-Cell mediated autoimmune disesase) in a subject in need thereof. The method comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of the invention, or a pharmaceutically acceptable salt thereof.

BENZOFURO[3,2-c] PYRIDINES AND RELATED ANALOGS AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS FOR THE TREATMENT OF OBESITY, METABOLIC SYNDROME, COGNITION AND SCHIZOPHRENIA

The present invention relates to benzofuro[3,2-c]pyridine and azepine analogs as serotonin sub-type 6 (5-HT6) modulators, pharmaceutical compositions including these compounds, methods of preparation, and use thereof. These compounds are useful in the treatment of central nervous system disorders including obesity, metabolic syndrome, cognition, schizophrenia, attention deficit hyperactivity disorder, bipolar disorder, rare and orphan diseases, and sleep disorders. The subject compounds have the structure of formula (I) with the substituents being described herein.